The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:
- Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
- What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?
People
Related Insights
July 15, 2025
Innovative Technology Insights
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…
July 15, 2025
Health Care Law Today
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…
July 15, 2025
Health Care Law Today
Colorado Medicaid: RAC Program Overhauled with Enhanced Transparency, Greater Provider Protections, and Increased Oversight
In June 2025, Colorado passed a new law that makes significant changes to the state’s Medicaid Recovery Audit Contractor (RAC) program….